摘要
目的探讨肿瘤患者血清细胞质胸昔激酶(TK1)在临床应用上的意义。方法利用免疫印迹增强化学发光法,检测138例肿瘤患者血清和28例健康体检者血清的TK1水平。结果肿瘤患者TK1阳性率为44.2%,健康体检者血清TK1阳性率为5.7%。鳞癌TK1阳性率为26.7%,腺癌TK1阳性率为53.3%。其中乳腺肿瘤、消化道肿瘤、其他肿瘤TK1阳性率较高,分别达57.8%、62.1%、53.5%。肺部肿瘤及宫颈肿瘤的TK1阳性率较低,分别为15.4%、14.3%。结论血清TK1检测在腺癌的辅助诊断上是一个有价值的标志物。
Objective To investigate serum from patients with tumor of chest of cytoplasmic kinase(TK1) in the clinical application of significance.Methods Using immunoblotting enhanced chemiluminescence detection in 138 cases,the serum of cancer patients and 28 healthy cases serum TK1 levels.Results Tumor patients TK1 positive rate was 44.2%,healthy persons serum TK positive rate was 5.7%.Squamous cell carcinoma TK1 positive rate was 26.7%,adenocarcinoma the positive rate of TK1 was 53.3%.The breast cancer,digestive tract tumor,other tumors in TK1 positive rate is higher,respectively 50.6%,61.1%,52.1%.Lung cancer and cervical cancer TK1 positive rate is low,respectively is 15.4%,14.3%.Conclusion Serum TK1 in the detection of adenocarcinoma of the aided diagnosis is a valuable marker.
出处
《中国医药指南》
2011年第34期32-35,共4页
Guide of China Medicine
关键词
细胞质胸昔激酶1
肿瘤
肿瘤标志物
免疫印迹增强化学发光法
Cytoplasmic thymidine kinase 1
Tumor
Tumor markers
Immunoblotting enhanced chemiluminescence method